Causal Effects of COVID-19 on the Risk of Thrombosis: A Two-Sample Mendel Randomization Study
Zhengran Li,Minghui Zeng,Tong Wu,Zijin Wang,Yuxin Sun,Ziran Zhang,Fanye Wu,Zejun Chen,Min Fu,Fanke Meng,Fangke Meng
DOI: https://doi.org/10.1055/a-2263-8514
2024-03-07
Thrombosis and Haemostasis
Abstract:Background Coronavirus disease 2019 (COVID-19) and thrombosis are linked, but the biomolecular mechanism is unclear. We aimed to investigate the causal relationship between COVID-19 and thrombotic biomarkers. Methods We used two-sample Mendelian randomization (MR) to assess the effect of COVID-19 on 20 thrombotic biomarkers. We estimated causality using inverse variance weighting with multiplicative random effect, and performed sensitivity analysis using weighted median, MR-Egger regression and MR Pleiotropy Residual Sum and Outlier (MR-PRESSO) methods. All the results were examined by false discovery rate (FDR) with the Benjamin and Hochberg method for this correction to minimize false positives. We used R language for the analysis. Results All COVID-19 classes showed lower levels of tissue factor pathway inhibitor (TFPI) and interleukin-1 receptor type 1 (IL-1R1). COVID-19 significantly reduced TFPI (odds ratio [OR] = 0.639, 95% confidence interval [CI]: 0.435–0.938) and IL-1R1 (OR = 0.603, 95% CI = 0.417–0.872), nearly doubling the odds. We also found that COVID-19 lowered multiple coagulation factor deficiency protein 2 and increased C–C motif chemokine 3. Hospitalized COVID-19 cases had less plasminogen activator, tissue type (tPA) and P-selectin glycoprotein ligand 1 (PSGL-1), while severe cases had higher mean platelet volume (MPV) and lower platelet count. These changes in TFPI, tPA, IL-1R1, MPV, and platelet count suggested a higher risk of thrombosis. Decreased PSGL-1 indicated a lower risk of thrombosis. Conclusion TFPI, IL-1R, and seven other indicators provide causal clues of the pathogenesis of COVID-19 and thrombosis. This study demonstrated that COVID-19 causally influences thrombosis at the biomolecular level. The data generated and codes used in the current study are available in this published article and [Supplementary File] associated with it. The data underlying this article are available in IEU OpenGWAS project, at https://gwas.mrcieu.ac.uk/. The data for this study came from a public database, so no such approval was required. M.Z. collected and organized the data. Z.L. analyzed the data and finished the writing. All authors participated in the writing and review of the article. * These authors contributed equally to the research. Received: 19 July 2023 Accepted: 17 November 2023 Accepted Manuscript online: 07 February 2024 Article published online: 05 March 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
peripheral vascular disease,hematology